1. Home
  2. MDWD vs FC Comparison

MDWD vs FC Comparison

Compare MDWD & FC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • FC
  • Stock Information
  • Founded
  • MDWD 2000
  • FC 1983
  • Country
  • MDWD Israel
  • FC United States
  • Employees
  • MDWD N/A
  • FC N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • FC Other Consumer Services
  • Sector
  • MDWD Health Care
  • FC Consumer Discretionary
  • Exchange
  • MDWD Nasdaq
  • FC Nasdaq
  • Market Cap
  • MDWD 208.2M
  • FC 239.1M
  • IPO Year
  • MDWD 2014
  • FC 1992
  • Fundamental
  • Price
  • MDWD $16.70
  • FC $19.52
  • Analyst Decision
  • MDWD Strong Buy
  • FC Strong Buy
  • Analyst Count
  • MDWD 2
  • FC 2
  • Target Price
  • MDWD $35.00
  • FC $27.00
  • AVG Volume (30 Days)
  • MDWD 94.5K
  • FC 135.1K
  • Earning Date
  • MDWD 08-14-2025
  • FC 07-02-2025
  • Dividend Yield
  • MDWD N/A
  • FC N/A
  • EPS Growth
  • MDWD N/A
  • FC N/A
  • EPS
  • MDWD N/A
  • FC 0.81
  • Revenue
  • MDWD $19,858,000.00
  • FC $279,943,000.00
  • Revenue This Year
  • MDWD $20.37
  • FC N/A
  • Revenue Next Year
  • MDWD $25.91
  • FC $1.23
  • P/E Ratio
  • MDWD N/A
  • FC $24.05
  • Revenue Growth
  • MDWD N/A
  • FC N/A
  • 52 Week Low
  • MDWD $14.14
  • FC $18.32
  • 52 Week High
  • MDWD $22.51
  • FC $44.16
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 28.98
  • FC 48.23
  • Support Level
  • MDWD $16.62
  • FC $18.88
  • Resistance Level
  • MDWD $17.35
  • FC $20.07
  • Average True Range (ATR)
  • MDWD 0.73
  • FC 0.67
  • MACD
  • MDWD -0.08
  • FC 0.12
  • Stochastic Oscillator
  • MDWD 5.13
  • FC 51.16

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.

Share on Social Networks: